Reg Jones will retire as chief financial officer of Stratagene, effective June 30, the company said last week. Jones, who will remain a company consultant, will be replaced by Steve Martin, the company's director of finance. Prior to joining Stratagene a year ago, he was the controller of GenProbe.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.